Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

624379.pdf (332.13 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2013-05-21

Llicència de publicació

cc-by (c) Navarro Ponz, Alfons et al., 2013
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/52827

MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin Lymphoma patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1371/journal.pone.0064716

Resum

Background: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways. Design and Methods: We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS). Results: The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P=0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P=0.048). Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also associated with a lower response rate (P=0.036). XPO5 (P=0.039) and TRBP (rs784567) (P=0.022) genotypes emerged as prognostic markers for DFS, and XPO5 was also associated with OS (P=0.033). In the multivariate analysis, only XPO5 emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039-6.620; P=0.041). Given the influence of XPO5 and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the shortest DFS (P=0.008) and OS (P=0.008). Conclusion: miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin lymphoma and can be used to identify patients likely to be chemoresistant or to relapse.

Matèries

Malaltia de Hodgkin, Micro RNAs, Limfomes

Matèries (anglès)

Hodgkin's disease, MicroRNAs, Lymphomas

Citació

Col·leccions

Articles publicats en revistes (Fonaments Clínics)

Citació

NAVARRO PONZ, Alfons, et al. MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin Lymphoma patients. PLoS One. 2013. Vol. 8, num. 5, pags. e64716. ISSN 1932-6203. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/52827

Exportar metadades

JSON - METS

Compartir registre